차의과학대학교
 
Home > 조혜영

조혜영

조혜영 교수

전공약제학(생물약제학), 임상약물동태학, 조제학, 약무행정학
연락처 031-881-7167 hycho@cha.ac.kr

학력

  • B.S. in Pharmacy, College of Pharmacy, Chonnam National University
  • M.S. in Biopharmaceutics, College of Pharmacy, Chonnam National University
  • Ph.D. in Biopharmaceutics, College of Pharmacy, Chonnam National University
  • Post-doc. Department of Pharmaceutics, State University of New York at Buffalo, USA

경력

  • (현) 차의과학대학교 약학대학 교수
  • (현) 국가신약개발사업단 투자심의위원회 심의위원
  • (현) 보건복지부 임상연구급여 평가위원회 위원
  • (현) 식품의약품안전처 중앙약사심의위원회(전문가)위원
  • (현) 건강보험심사평가원 약제급여평가위원회 위원
  • (현) 한국연구재단 연구윤리위원회 위원
  • (현) (사)대학연구윤리협의회 집행이사
  • (현) (사)한국약제학회 부회장/이사
  • (현) 약학교육협의회 보건의약관계법규분과회 부회장
  • 식품의약품안전청 보건연구관

    • [수상경력]
  • 식품의약품안전처장 표창, 2021.11.26
  • 학술대상, (사)한국약제학회, 2020.11.19
  • 보건복지부장관 유공 표창(임상시험 분야), 2019.05.17
  • 2017 식품의약품안전처 연구개발사업 우수상, 2018.03.28
  • KAPSA Award of Outstanding Contribution, 한미약학자연합회, 2017.11.14
  • The Korean-American Pharmaceutical Scientists Association, KAPSA
  • 법제과학상, (사)한국FDC법제학회, 2017.11.09
  • 산학기술상, (사)한국약제학회, 2015.11.19
  • 제25회 과학기술 우수논문상, 한국과학기술단체총연합회, 2015.07.02
  • 업무유공자상(차관급표창), 식품의약품안전청, 2010.01.04
  • 학술장려상, 한국약제학회, 2006.11.30
  • 우수논문발표상, 대한약학회, 2003.10.18
  • 우수학술포스터상, 한국약제학회, 2001.11.15
  • NAGAI Foundation Awards, Controlled Release Society, 2001.06.27


    • [연구실 소개]

    약물을 체내에 투여하게 되면 흡수 (absorption, A), 분포 (distribution, D), 대사 (metabolism, M) 및 배설 (elimination, E) 등의 과정을 거치게 되는데 이러한 ADME 과정을 속도론적 입장에서 해석하는 학문이 약물속도론 (pharmacokinetics)입니다. 모델을 가정하여 투약 후의 혈중농도, 소실반감기, 대사속도, 배설속도 및 축적량 등을 정량적으로 예측함으로써 ① 생체 내에서의 약물현상의 기구를 해명하고, ② 투여량, 투여간격 및 투여 제형을 적절히 결정하며, ③ 나아가서는 보다 유효하고 안전성이 높은 의약품의 개발에 기여하고자 하는 것을 목적으로 합니다.
    우리 연구실은 동물실험에서 약물의 체내동태를 속도론적으로 해석하여 분포용적, 속도정수 등의 파라미터를 산출한 후 animal scale-up의 방법으로 동물 데이터로부터 사람의 약물동태를 예측하고, 또한 약물 농도(PK)와 약물 효과(PD)를 연결할 수 있는 모델 구축 연구를 수행하고 있어, 실제 환자에게 약물의 효과가 충분히 발휘되고 안전성이 확보되도록 하는 약물 투여 용법 적정화에 기여할 수 있을 것으로 기대하고 있습니다.

논문

  • Approaches for estimating the clinical starting dose of new dosage forms: An example of a long-acting injectable formulation of finasteride, Int. J. Pharm., 631C, 122510-122519 (2022)
  • Parent-Metabolite Pharmacokinetic Modeling of Formononetin and Its Active Metabolites in Rats after Oral Administration of Formononetin Formulations, Pharmaceutics, 15(1), 45-60 (2022)
  • Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically-based pharmacokinetic (PBPK) modeling: Analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population, Arch. Toxicol., 96, 2687–2715 (2022)
  • Strategies for developing Alzheimer’s disease treatments: Application of population pharmacokinetic and pharmacodynamic models, J. Pharm. Invest., 52(5), 519-538 (2022)
  • Population pharmacokinetic (Pop-PK) analysis of torsemide in healthy Korean males considering CYP2C9 and OATP1B1 genetic polymorphisms, Pharmaceutics, 14(4), 771-795 (2022)
  • Population pharmacokinetic modeling and simulation of choline in healthy Korean subjects after oral administration of choline alfoscerate, J. Pharm. Invest., 52(3), 331-339 (2022)
  • In vitro and in vivo evaluations of a 3-month sustained-release microsphere depot formulation of leuprolide acetate, J. Pharm. Invest., 52(1), 129-138 (2022)
  • Long-acting injectable donepezil microspheres: Formulation development and evaluation, Control. Release, 340, 72-86 (2021)
  • Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method, Toxicol., 95(11), 3515-3537 (2021)
  • Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704, Pharmaceutics, 13(9), 1406, DOI: 10.3390/pharmaceutics13091406 (2021)
  • Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats, Chemosphere, 286, DOI: 10.1016/j.chemosphere.2021.131706 (2021)
  • Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects, Pharmaceutics, 13(5), 754, DOI: 10.3390/pharmaceutics13050754 (2021)
  • Palmul-Tang, a Korean Medicine, Promotes Bone Formation via BMP-2 Pathway in Osteoporosis, Front Pharmacol., DOI: 10.3389/fphar.2021.643482 (2021)
  • Pharmacokinetic-pharmacodynamic modeling approach for dose prediction of the optimal long-acting injectable formulation of finasteride, J. Pharm., DOI: 10.1016/j.ijpharm.2021.120527 (2021)
  • Human risk assessment of di‑isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di‑isobutyl phthalate and its major metabolite mono‑isobutyl phthalate, Toxicol., 95, 2385-2402 (2021)
  • Evaluation of Lidocaine and Metabolite Pharmacokinetics in Hyaluronic Acid Injection, Pharmaceutics, 12, 374; DOI:10.3390/pharmaceutics13020203 (2021)
  • Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma, Pharm. Anal., 11 (2021) 351-363
  • In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching, Pharm. Biomed. Anal., DOI: 10.1016/j.jpba.2021.113931 (2021)
  • Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study, Pharm. Anal., 11 (2021) 444-457
  • Simultaneous determination of asarinin, β-eudesmol, and wogonin in rats using UPLC-MS/MS and its application to pharmacokinetic studies following administration of standards and Gumiganghwal-tang, Chromatogr., DOI: 10.1002/bmc.5021 (2020)
  • Simultaneous determination of three iridoid glycosides of Rehmannia glutinosa in rat biological samples using a validated hydrophilic interaction?UHPLC?MS/MS method in pharmacokinetic and in vitro studies, Sep. Sci., 43(22), 4148-4161 (2020)
  • Toxicokinetics of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rats: UPLC-ESI-MS/MS method development for the simultaneous determination of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rat plasma, urine, feces, and 11 various tissues collected from a toxicokinetic study, Food Chem. Toxicol., DOI: 1016/j.fct.2020.111747 (2020)
  • Pharmacokinetics of bioactive components after oral administration of Bojungikgi-tang in Korean subjects, Pharm. Invest., 50(6), 593-602 (2020)
  • Population Pharmacokinetic analysis of tiropramide in healthy Korean subjects, Pharmaceutics, 12, 374-385 (2020)
  • Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies, Chromatogr., DOI: 10.1002/bmc.4848 (2020)
  • Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate, Toxicol., 94(7), 2377-2400 (2020)
  • Gender differences in pharmacokinetics of perfluoropentanoic acid using non-linear mixed effect modeling in rats, Toxicol., 94(5), 1601-1612 (2020)
  • Translational toxicology of sex specific PFNA clearance in rat and human, Toxicol., 94(2), 649-650 (2020)
  • A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits, Molecules, 25, 663 (2020)
  • Pharmacokinetic comparison of epinastine using developed human plasma assays, Molecules, 25, 209 (2020)
  • Development of level a in vitro–vivo correlation for electrosprayed microspheres containing leuprolide: physicochemical, pharmacokinetic, and pharmacodynamic evaluation, Pharmaceutics, 12(1), 36 (2020)
  • A sensitive UPLC-ESI-MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma, Pharm. Invest., 50(2), 159-172 (2020)
  • Population pharmacokinetics of cis-, trans-, and total cefprozil in healthy male Koreans, Pharmaceutics, 11, 531 (2019)
  • Gender differences in pharmacokinetics and tissue distribution of 4‑n‑nonylphenol in rats, Toxicol., 93(11), 3121-3139 (2019)
  • Response to Hethey et al., 2019 Letter to the Editor in Archives of Toxicology, Toxicol., 93(10), 3033-3035 (2019)
  • Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method, Chromatogr. B, 1126-1127, DOI 10.116/ /j.jchromb.2019.121743, 1126-1127, 121743 (2019)
  • Simultaneous determination diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry, Pharm. Biomed. Anal., 173 (2019), 108-119 (2019)
  • Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: In vitro–in vivo extrapolation and allometric scaling, Pharmaceutics, 11, 168 (2019)
  • Exploring sex-differences in human health risk assessment for PFNA and PFDA using a PBPK model, Toxicol., 93(2), 311-330 (2019)
  • Comparison of UPLC-MS/MS and HPLC-UV method for the determination of zaltoprofen in human plasma, Pharm. Invest., 49(6), 613-624 (2019)
  • Pharmacokinetics profile of Kaurenoic acid after oral administration of Araliae Continentalis Radix extract powder to humans, Pharmaceutics, 10(4), 253 (2018)
  • Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery, Pharm. Res., 41, 797-814 (2018)
  • Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to Pharmacokinetic Study, Chromatogr. B, 1095, 214-225 (2018)
  • Simultaneous Determination of Decursin, Decursinol Angelate, Nodakenin, and Decursinol of Angelica gigas Nakai in Human Plasma by UHPLC-MS/MS: Application to Pharmacokinetic Study, Molecules, 23(5), 1019 (2018)
  • Pharmacokinetic/Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats, Molecules, 23(4), 909 (2018)
  • Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach, J. Pharm. Sci., 118, 154-164 (2018)
  • Research on the advancement of standards and specifications of biologics in Korea, Biologicals, 53, 76-77 (2018)
  • Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets, J. Clin. Pharmacol. Ther., 56(6), 292-300 (2018)
  • Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model, Arch. Toxicol., 92, 1113-1131 (2018)

저서/역서/편서

  • 임상실무 약학, 도서출판 신일북스 (2020) ISBN 978-89-5702-483-6
  • 제2호 한국임상시험백서, 도서출판 국가임상시험지원재단/보건복지부 (2019) ISBN 978-89-9691-091-6
  • 약제학리뷰, 도서출판 신일서적 (2019) ISBN 979-11-8884-754-9
  • 생물약제학과 약동학(수정2판), 도서출판 신일서적 (2019) ISBN 979-11-8884-737-2
  • 임상시험 길잡이, 도서출판 한국보건산업진흥원/보건복지부 (2018)
  • 한국임상시험백서, 도서출판 한국임상시험산업본부 (2016) ISBN 978-89-9691-091-6
  • 약국실무, 도서출판 신일북스 (2016) ISBN 978-89-5702-452-2
  • 약제학 리뷰(수정판), 도서출판 신일북스 (2016) ISBN 978-89-5702-395-2
  • 약제학총서2 수정판 생물약제학과 약동학, 도서출판 신일북스 (2015) ISBN 978-89-5702-431-7
  • 조제학, 도서출판 신일북스 (2015) ISBN 978-89-5702-419-5
  • 약제학리뷰, 도서출판 신일북스 (2014) ISBN 978-89-5702-395-2
  • 생물약제학과 약동학, 도서출판 신일북스 (2013) ISBN 978-89-5702-349-1
  • 약물상호작용의 기전적 이해, 도서출판 신일상사, (2005) ISBN 89-5702-083-7


    • [특허]
  • 생리학적 약물동태학 핵심 모델. 출원 2020.11.23
  • 전기분무기술을 이용한 루프롤라이드 함유 서방성미립구의 제조방법. 출원(제17-108842호) 2017.08.28
  • L-THP를 유효성분으로 포함하는 약물남용 치료제. 등록 (제10-1054093호) 2011.07.28